ISOVUE-250 Drug Patent Profile
✉ Email this page to a colleague
When do Isovue-250 patents expire, and what generic alternatives are available?
Isovue-250 is a drug marketed by Bracco and is included in two NDAs.
The generic ingredient in ISOVUE-250 is iopamidol. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the iopamidol profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Isovue-250
A generic version of ISOVUE-250 was approved as iopamidol by HAINAN POLY on February 27th, 2023.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for ISOVUE-250?
- What are the global sales for ISOVUE-250?
- What is Average Wholesale Price for ISOVUE-250?
Summary for ISOVUE-250
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 72 |
| Clinical Trials: | 20 |
| Patent Applications: | 4,643 |
| Drug Prices: | Drug price information for ISOVUE-250 |
| DailyMed Link: | ISOVUE-250 at DailyMed |
Recent Clinical Trials for ISOVUE-250
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| NYU Langone Health | N/A |
| National Cancer Institute (NCI) | N/A |
| M.D. Anderson Cancer Center | N/A |
Pharmacology for ISOVUE-250
| Drug Class | Radiographic Contrast Agent |
| Mechanism of Action | X-Ray Contrast Activity |
US Patents and Regulatory Information for ISOVUE-250
ISOVUE-250 is protected by zero US patents and one FDA Regulatory Exclusivity.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bracco | ISOVUE-250 | iopamidol | INJECTABLE;INJECTION | 018735-007 | Jul 6, 1992 | AP | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Bracco | ISOVUE-250 | iopamidol | INJECTABLE;INJECTION | 020327-002 | Oct 12, 1994 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ISOVUE-250
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Bracco | ISOVUE-250 | iopamidol | INJECTABLE;INJECTION | 018735-007 | Jul 6, 1992 | 4,001,323 | ⤷ Start Trial |
| Bracco | ISOVUE-250 | iopamidol | INJECTABLE;INJECTION | 020327-002 | Oct 12, 1994 | 4,001,323 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ISOVUE-250
See the table below for patents covering ISOVUE-250 around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Argentina | 211853 | PROCEDIMIENTO PARA LA PREPARACION DE LAS NUEVAS BIS-(DIHIDROXIPROPI-AMIDAS)DE ACIDO 5-HIDROXIPROPIONILAMINO-2,4,6-TRIYODOISOFTALICO FACILMENTE SOLUBLES EN AGUA | ⤷ Start Trial |
| Austria | 340582 | ⤷ Start Trial | |
| Austria | 342579 | ⤷ Start Trial | |
| Austria | 349449 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch